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Abstract
Objectives
The study aimed to survey maraviroc use and assess effectiveness and durability of mara-
viroc-containing antiretroviral treatment (ART) in routine practice across Europe.
Methods
Data were retrieved from 26 cohorts in 8 countries comprising adults who started maraviroc
in 2005–2016 and had�1 follow-up visit. Available V3 sequences were re-analysed cen-
trally for tropism determination by geno2pheno[coreceptor]
.
Treatment failure (TF) was
defined as either virological failure (viral load >50 copies/mL) or maraviroc discontinuation
for any reason over 48 weeks. Predictors of TF were explored by logistic regression analy-
sis. Time to maraviroc discontinuation was estimated by Kaplan-Meier survival analysis.
Results
At maraviroc initiation (baseline), among 1,381 patients, 67.1% had experienced�3 ART
classes and 45.6% had a viral load <50 copies/mL. Maraviroc was occasionally added to
the existing regimen as a single agent (7.3%) but it was more commonly introduced along-
side other new agents, and was often (70.4%) used with protease inhibitors. Accompanying
drugs comprised 1 (40.2%), 2 (48.6%) or�3 (11.2%) ART classes. Among 1,273 patients
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with available tropism data, 17.6% showed non-R5 virus. Non-standard maraviroc use also
comprised reported once daily dosing (20.0%) and a total daily dose of 150mg (12.1%).
Over 48 weeks, 41.4% of patients met the definition of TF, although the 1-year estimated
retention on maraviroc was 82.1% (95% confidence interval 79.9–84.2). Among 1,010 sub-
jects on maraviroc at week 48, the viral load was >50 copies/mL in 19.9% and >200 copies/
mL in 10.7%. Independent predictors of TF comprised a low nadir CD4 count, a detectable
baseline viral load, previous PI experience, non-R5 tropism, having�3 active drugs in the
accompanying regimen, and a more recent calendar year of maraviroc initiation.
Conclusions
This study reports on the largest observation cohort of patients who started maraviroc across 8
European countries. In this overall highly treatment-experienced population, with a small but
appreciable subset that received maraviroc outside of standard treatment guidelines, maraviroc
was safe and reasonably effective, with relatively low rates of discontinuation over 48 weeks
and only 2 cases of serum transaminase elevations reported as reasons for discontinuation.
Introduction
Among antiretrovirals approved for the treatment of HIV-1 infection, maraviroc and the recently
approved ibalizumab are unique in targeting a host protein rather than a viral enzyme. By engag-
ing the transmembrane helices of the CC chemokine receptor 5 (CCR5), maraviroc disrupts the
geometry of the multi-point interaction between the second extracellular loop of CCR5 and the
V3 loop of HIV-1 glycoprotein (gp) 120, allosterically preventing R5 virus from binding. As a
result of the targeted mode of action, a tropism test demonstrating the presence of CCR5-tropic
(R5) virus is a prerequisite for maraviroc use. During clinical development, tropism was deter-
mined with the Trofile phenotypic test provided by Monogram Biosciences (CA, USA). Subse-
quently, largely retrospective validation studies established genotypic tropism testing as an
alternative, based on the analysis of the gp120 V3 sequence through an automated predictive algo-
rithm, most commonly the geno2pheno[coreceptor] system [1]. Comparative evaluations demon-
strated a good albeit not perfect technical correlation between phenotypic and genotypic tropism
testing [2–4]. Importantly, genotypic tropism testing was found to predict virological outcome
within both retrospective evaluations of clinical trial data and in observational cohorts [2,5–7].
The efficacy and safety of maraviroc have been demonstrated in phase 3 clinical trials of
both antiretroviral treatment (ART)-naïve and ART-experienced subjects with R5 virus [8–
12]. While in the US maraviroc is approved for both indications, in Europe it is approved only
for the treatment of ART-experienced subjects. In clinical practice, however, maraviroc has
been used in a variety of clinical scenarios [13–18].
With the aim of gaining a comprehensive understanding of maraviroc use, this multicentre
observational cohort study surveyed reasons for starting maraviroc and measured the efficacy
and durability of maraviroc-containing regimens across Europe. A secondary objective was to
determine the performance of genotypic tropism testing in relation to virological outcomes.
Patients and methods
Study population and data collection
Subjects eligible for inclusion were HIV-1 positive adults who started their first maraviroc-con-
taining ART regimen between January 2005 and December 2013 within routine clinical practice,
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and had�1 follow-up visit after receiving�1 dose of maraviroc. Fully anonymised data available
from individual electronic databases and clinical cohorts were collected as part of a formal Euro-
pean audit of clinical service; no ethics permission was required, and the audit was registered with
the Royal Liverpool University Hospital in the United Kingdom. A total of 26 clinical cohorts in 8
European countries participated. Each centre adhered to local research governance regulations
concerning the collection and analysis of routinely collected, anonymised clinical data for audit
purposes. Data submission to the central audit repository occurred through a structured case
record form that collected simple demographic data (age, gender, ethnicity), current and nadir
CD4 cell count, CD4 cell count and plasma HIV-1 RNA load at the start of maraviroc (baseline,
measured within 6 weeks prior to starting maraviroc) and during follow-up, ART history (num-
ber and classes of antiretrovirals received prior to baseline, calendar year of first maraviroc use,
reasons for starting and stopping maraviroc, and antiretrovirals used together with maraviroc),
results of drug resistance and tropism testing performed at any time before and after starting mar-
aviroc, and HIV-1 subtype if known. We used objective measures from the database in order to
classify the context of maraviroc use. ART-naïve patients were classified on the objectively verified
absence of previous ART use. In ART-experienced individuals, treatment was classified as “ART
switch” when one or more components of the existing regimen were changed alongside the intro-
duction of maraviroc, and as “ART intensification” when maraviroc was added as a single agent
to the existing regimen. These treatment categories were subdivided based on suppressed or
detectable viral load (i.e., HIV-1 RNA either< or� 50 copies/mL) prior to maraviroc initiation.
Viral tropism and drug susceptibility
Results of genotypic tropism testing were verified by a centralised re-analysis of gp120 V3
sequences using geno2pheno[coreceptor] version 2.5 [1] with a false positive rate (FPR) defining
R5-tropic virus set at>10% in case of triplicate sequences or>20% in case less than three
sequences were available, as per published European guidelines [19]. Centres using phenotypic
testing submitted results obtained with the Monogram Trofile or Enhanced Sensitivity Trofile
assay. A valid baseline tropism assay result was measured using plasma collected within 90 days
prior to starting maraviroc in viraemic patients. Older results obtained from either plasma,
whole blood or peripheral blood mononuclear cells (PBMC) where accepted provided the
patient had not experienced viraemia between the tropism test and the start of maraviroc, as per
European guidelines [19]. The Genotypic Susceptibility Score (GSS) of the regimen accompa-
nying maraviroc was derived from protease, reverse transcriptase, and integrase sequences using
the Stanford’s HIVdb 8.1 algorithm (www.hivdb.stanford.edu), whereby each drug in the regi-
men was assigned a susceptibility score based on the estimated levels of drug resistance: suscepti-
ble and potential low-level resistance = 1; low-level and intermediate resistance = 0.5; and high-
level resistance = 0. For enfuvirtide, gp41 sequences were interpreted using HIV GRADE (http://
www.hiv-grade.de/grade/deployed/grade.pl?program=hivalg). In the absence of an integrase or
gp41 sequence, integrase inhibitors and enfuvirtide were assumed to be fully active in case of
first use or previous use without failure (score = 1) and not active (score = 0) in case of previous
use with documented failure. HIV-1 subtypes were assigned based on all pol sequences using the
Rega subtyping tool 3.0 (http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/
typingtool) and the Comet algorithm (https://www.ncbi.nlm.nih.gov/pubmed/25120265). In
case of discordant results between the two algorithms, the subtype was set as undetermined.
Treatment outcomes for maraviroc-containing regimens and statistical analysis
The date of maraviroc initiation was considered the baseline for the study. Treatment out-
comes were measured over 48 weeks (allowing a window of +/- 6 weeks). Treatment failure
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(TF) was defined by either virological failure (VF, viral load>50 copies/mL while on mara-
viroc) or maraviroc discontinuation prior to week 48 for any cause. The VF analysis comprised
patients who remained on maraviroc at week 48. Time to maraviroc discontinuation was esti-
mated by survival analysis using the Kaplan-Meier method; where data were available past
week 48, these were retained in the analysis. Predictors of TF and VF were analysed by univari-
ate and multivariable logistic regression. All p-values were calculated by a univariate mixed
logistic model taking into account the clustering effect of the clinical centre. In the multivari-
able models, a backward stepwise selection method was employed starting from a model with
all variables showing an association with the outcome of interest with a p-value� 0.2 accord-
ing to the univariate analysis. These models employed a stepwise exclusion criterion of vari-
ables with p-values >0.2, except for viral tropism that was manually included in all models. In
the final multivariable models, all variables retained by the selection method were simulta-
neously adjusted. Statistical analysis was performed using the STATA version 13.0 software
package.
Results
Study population at baseline
Data were retrieved from 26 clinical centres in 8 countries totalling 1,381 patients, and com-
prising 538 from the United Kingdom and Ireland, 291 from Italy, 259 from Germany, 206
from Spain, 43 from France, 30 from Belgium, and 14 from Luxemburg. The characteristics of
the study population at the time of starting maraviroc (baseline) are summarized in Table 1.
Most patients were males of white ethnicity (718/1,381, 52%), 754/1,381 (54.6%) with a nadir
CD4 count <200 cells/mm3, and 782/1,381 (56.6%) with a current CD4 cell count�350 cells/
mm3. Almost half (630/1,381, 45.6%) had a suppressed viral load (<50 copies/mL). The overall
cohort was heavily ART-experienced, with 718/1,381 (52.0%) having received�7 antiretrovi-
ral drugs and about two-thirds (926/1,381, 67.1%) having experienced�3 drug classes includ-
ing protease inhibitors (PIs) in 1213/1,381 (87.8%) and integrase inhibitors in 651/1,381
(47.1%).
Viral tropism
Tropism assay results were available for 1,273 (92.3%) participants: 1,075 through genotypic
testing and 189 through a phenotypic assay (Trofile in 118, Enhanced Sensitivity Trofile in
58, unspecified in 13). In 9 cases the type of assay was not specified and no V3 sequences
were available for re-analysis. Both phenotypic and genotypic tropism assay results were
available in 14 cases, with only one discordant case where the phenotypic result was consid-
ered. Tropism testing was performed using plasma HIV-1 RNA in 696 cases and HIV-1
DNA (from whole blood or PBMC) in 561; in 16 cases the source was not specified. The tro-
pism result was R5 in 1,049/1,273 (82.4%) and non-R5 in 224/1,273 (17.6%). The FPR
results were available for 1,036/1,075 genotypic tropism assays and comprised: <10% in 104
cases, 10% to 20% in 133 cases, 20% to 40% in 249 and�40% in 550 cases. The median FPR
value (IQR) was 50.5 (33.9–78.1) for results assigned as R5 and 10.4 (4.6–15.5) for those
assigned as non-R5.
GSS and HIV-1 subtypes
The GSS of the regimen accompanying maraviroc was available for 661/1,381 (47.9%) subjects,
including 393/709 (55.4%) subjects that started maraviroc with HIV-1 RNA�50 copies/mL.
The GSS was <1 in 83/661 (12.6%), 1 in 254/661 (38.4%), 2 in 228/661 (34.5%), and�3 in 96/
Use of maraviroc in routine care: A European survey
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661 (14.5%). The viral subtype was available in 794/1,381 patients (57.5%): most carried sub-
type B (606/794, 76.3%), followed by C (36, 4.5%), A (33, 4.2%), CRF02_AG (19, 2.4%), G (12,
1.5%), others (43, 5.4%), and unassigned subtype (45, 5.7%).
Table 1. Characteristics of the study population at the start of maraviroc (n = 1,381).
Characteristic
Age, median years (IQR) 46 41–52
Males, n (%) 1,052 76.7%
Ethnicity, n (%) White Caucasian 718 52.0%
Black African 231 16.7%
Asian 18 1.3%
Other/Unknown 414 30.0%
Nadir CD4 count
(cells/mm3)
<50 285 20.6%
50–199 469 34.0%
200–349 290 21.0%
�350 148 10.7%
NA 189 13.7%
Baseline CD4 count (cells/mm3) <50 51 3.7%
50–199 236 17.1%
200–349 257 18.6%
�350 782 56.6%
NA 55 4.0%
HIV-1 RNA
(copies/mL)
<50 630 45.6%
50–199 147 10.6%
200–4,999 253 18.3%
5,000–99,999 189 13.7%
�100,000 120 8.7%
NA 42 3.0%
Prior antiretrovirals, n (%) <3 268 19.4%
3–6 341 24.7%
7–10 349 25.3%
�10 369 26.7%
NA 54 3.9%
Prior drug classes, n (%) <3 455 32.9%
3 482 34.9%
�3 444 32.2%
PI experienced, n (%) 1,213 87.8%
NRTI experienced, n (%) 1,249 90.4%
NNRTI experienced, n (%) 846 61.3%
InSTI experienced, n (%) 651 47.1%
Enfuvirtide experienced, n (%) 84 6.1%
Calendar year
of maraviroc start
2005–2008 249 18.0%
2009–2010 496 35.9%
2011 311 22.5%
2012–2016 325 23.5%
Abbreviations: ART, antiretroviral treatment; NA, not available; PI, protease inhibitor; NRTI, nucleos(t)ide reverse
transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; InSTI, integrase strand-transfer
inhibitor.
https://doi.org/10.1371/journal.pone.0225381.t001
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Patterns of maraviroc use
Clinician-reported reasons for maraviroc initiation were available in 1,297/1,381 (93.9%)
patients. Most patients that started maraviroc were described as treatment experienced.
Among the reported reasons, VF accounted for 547/1,297 (39.6%) initiations, whereas a
change of a virologically suppressive regimen was reported in 465/1,297 (35.9%) as a result of
toxicity (374, 27.1%) or other reasons (91, 6.6%). Intensification of suppressive ART was
described in 104/1,297 (8.0%) subjects and the reasons comprised low CD4 cell counts (56,
4.1%) and miscellaneous other reasons including aiming to improve ART activity in the cen-
tral nervous system (CNS). Maraviroc was started in ART-naïve subjects in 49/1,297 (3.5%)
cases. For the remaining 132/1,297 (9.6%) subjects, the reason for maraviroc initiation was not
reported. For analytic purposes, the context of maraviroc initiation was classified using objec-
tive measures (Table 2). Among the 1,381 patients with an objectively classifiable reason for
maraviroc initiation, 882 (63.9%) switched ART regimen (i.e., added maraviroc while stopping
and/or adding at least another agent), comprising 441 (31.9%) with a detectable viral load, 409
(29.6%) with an undetectable viral load and 32 (2.3%) with unknown viral load. The existing
ART regimen was intensified with maraviroc as a single add-on agent in 101/1,381 (7.3%) sub-
jects, comprising 50 (3.6%) with a detectable viral load, 50 (3.6%) with an undetectable viral
load, and 1 (0.1%) with unknown viral load. ART-naïve maraviroc use accounted for 46/1,381
(3.3%) cases.
The most frequently employed total daily dose of maraviroc was reported as 300mg (733/
1,381, 53.1%), followed by 600mg (228/1,381, 16.5%), 150mg (167/1,381, 12.1%) and 1,200mg
(31/1,381, 2.2%); the dose was not reported in 222/1,381 (16.1%) of cases. The dosing schedule
was reported as twice daily in 661/1,381 (47.9%) subjects, once daily in 276/1,381 (20.0%), and
was not reported in 444/1,381 (32.2%). The accompanying drugs belonged to 1, 2, and 3 or
more classes in 518/1,381 (40.2%), 626/1,381 (45.3%) and 144/1,381 (10.4%) regimens, respec-
tively (Table 3); 906 (70.4%) regimens included PIs.
Treatment outcomes of maraviroc containing regimens
Duration of follow-up and number of visits differed from centre to centre because of varying
clinical practice. Several sites provided only data covering 48 weeks after maraviroc initiation,
whereas others reported all available follow-up. During 1,845 person-years of follow-up, mara-
viroc was discontinued in 354 patients. The survival analysis (Fig 1) showed a stable rate of
Table 2. Context of maraviroc use.
ART status HIV-1 RNA
(copies/mL)
n % of all cases
Starting ART from naive >50 46 3.3%
Switching ART regimen <50 409 29.6%
�50 441 31.9%
NA 32 2.3%
Intensification of ART regimen <50 50 3.6%
�50 50 3.6%
NA 1 0.1%
Unknown <50 169 12.2%
�50 175 12.7%
NA 8 0.6%
Abbreviations: ART, antiretroviral treatment; NA, not available
https://doi.org/10.1371/journal.pone.0225381.t002
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maraviroc discontinuation during the first 2 years, with a 1-year estimated probability of con-
tinuing maraviroc of 82.1% (95% CI, 79.9–84.2). Durability was estimated based on patients
continuing to receive maraviroc, regardless of VF. Reasons for maraviroc discontinuation
were reported for 294 patients and comprised VF (92/294, 31.4%), treatment simplification
Table 3. Antiretroviral treatment classes used with maraviroc.
Number
of classes
Class n %
1 Any 518 37.5
PI 333 24.1
NRTI or NNRTI 161 11.7
InSTI 20 1.4
2 PIs 4 0.3
2 Any 626 45.3
NRTI + PI 111 8.0
2–3 NRTIs + PI 192 13.9
NRTI + NNRTI 39 2.8
1–2 NRTIs + 2 PIs 2 0.1
Other combination 282 20.4
3 Any 120 8.7
PI + NRTI + NNRTI 13 0.9
Other combination 107 7.7
4 Any 24 1.7
Not available 93 6.7
Abbreviations: PI, protease inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor
NNRTI, non-nucleoside reverse transcriptase inhibitor; InSTI, integrase strand-transfer inhibitor.
https://doi.org/10.1371/journal.pone.0225381.t003
Fig 1. Kaplan-Meier curve of the cumulative probability of continuing maraviroc after its initiation in the study
cohort. The line indicates the estimate, shadows represent the 95% confidence intervals. MVC, maraviroc. The
number of patients receiving maraviroc are indicated as “Number at risk”. The vertical line shows the 48 weeks cut-off
point; all available data up to 24 months of follow-up were used.
https://doi.org/10.1371/journal.pone.0225381.g001
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(27/294, 9.3%), clinician’s decision (29/294, 9.8%), toxicity (53/294, 18.1%), non-adherence
(37/294, 12.7%), patient’s choice (10/294, 3.4%), non-R5 tropism (6/294, 2.0%), loss to follow-
up (6/294, 2.0%), death (6/294, 2.0%), and other reasons (27/294, 9.3%). Reported toxicity rea-
sons comprised two cases of serum transaminases elevation.
Overall, 572/1,381 (41.4%, 95% CI: 38.9–44.1) subjects experienced TF over 48 weeks of fol-
low-up. The logistic regression analysis of factors associated with TF is shown in Table 4. After
Table 4. Univariate and multivariable logistic regression analysis of factors associated with treatment failure over 48 weeks.
Univariate analysis Multivariablee analysis
N Failure (%) p-value AOR 95% CI p-value
Age (years) <35 151 50.3 0.04 1.00 0.05
�35 1212 40.1 0.68a 0.46–0.99
35–44 458 38.0
45–54 532 42.7
�55 222 38.3
Ethnicity White Caucasian 718 40.8 0.17 NI
Black African 231 42.9
Asian 18 33.3
Other 29 51.7
Nadir CD4 count (cells/mm3) <50 285 51.9 <0.01 1.00
50–199 469 41.4 0.70 0.50–0.97 0.03
200–349 290 39.7 0.73 0.51–1.05 0.09
�350 148 35.1 0.48 0.30–0.77 <0.01
Baseline CD4 count (cells/mm3) <50 51 58.8 <0.01 NI
50–199 236 47.9
200–349 257 39.3
�350 782 37.7
Baseline HIV-1 RNA (cps/mL) <50 630 32.5 <0.01 1.00
50–199 147 48.3 1.82 1.01–3.27 0.04
200–4,999 253 51.4 2.45 1.46–4.11 <0.01
5.000–99,999 189 39.7 1.80 1.02–3.33 0.04
�100,000 120 54.2 2.98 1.67–6.03 <0.01
Drugs experienced (n) <3 329 36.5 0.11 NI
3–6 345 43.8
7–10 320 47.8
�10 333 39.9
ART classes experienced, n 1 455 36.9 0.01 NI
2–3 926 43.6
Maraviroc daily dose �300 mg 167 50.9 <0.01 0.72 0.49–1.06 0.09
<300 mg 992 38.8 1.00
Maraviroc schedule Once daily 276 46.0 <0.01 NI
Twice daily 661 38.6
Context of maraviroc use Naive 46 41.3 <0.01 0.48 0.19–1.20 0.12
Switch, suppressed VL 409 32.3 1.00
Switch, detectable VL 441 49.0 1.21 0.68–2.16 0.51
Intensify, suppressed VL 50 42.0 1.52 0.79–2.94 0.21
Intensify, detectable VL 50 56.0 1.42 0.63–3.23 0.40
Previous PI experience Yes 1218 42.9 0.04 1.62 1.05–2.48 0.03
No 163 30,7 1.00
(Continued)
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adjustment, the odds of TF were increased by a low nadir CD4 count, a detectable baseline
viral load, having previously experienced PI therapy, a non-R5 tropism result, a GSS of the reg-
imen accompanying maraviroc�3 and starting maraviroc after 2011. There was also a mar-
ginal effect of age.
Of the 1,010 patients still on maraviroc at week 48, 201 (19.9%) had a viral load>50 copies/
mL, including 93 (9.2%) with levels between 50 and 200 copies/mL and 108 (10.7%) with levels
>200 copies/mL. The logistic regression analysis of factors associated with VF is shown in
Table 5. After adjustment, the odds of VF were increased by a low nadir CD4 count, a detect-
able baseline viral load, and having previously experienced PI therapy. There was also a mar-
ginal effect of age.
Tables 6 and 7 show the outcomes for the relatively high number of subjects that received
maraviroc outside of standard treatment guidelines. Overall, TF was more likely in subjects
receiving maraviroc once daily, those receiving a total daily dose of 150mg and those with
non-R5 tropism (Table 6), whereas only non-R5 tropism showed a marginal effect on the
occurrence of VF (Table 7).
Discussion
This study reports the largest data set of maraviroc-containing treatment cases ever collected
from routine clinical practice. We asked clinical sites to include all their patients initiating
maraviroc outside clinical trials to assess the use and effectiveness of maraviroc across Europe,
in a time frame spanning from 2005 to 2016. Based on this survey enrolling cases through 26
different clinical sites in 8 European countries, we observed that maraviroc was used in
Table 4. (Continued)
Univariate analysis Multivariablee analysis
N Failure (%) p-value AOR 95% CI p-value
Viral tropism R5 1061 39.1 <0.01 1.00
Non-R5 165 50.3 1.65 1.20–2.27 <0.01
FPR �10 51 51.0 <0.01 NI
(10–20] 68 48.9
(20–40] 156 37.3
�40 330 40.0
GSS of accompanying regimen <1 83 27.7 <0.01 1.00
1–2 254 37.8 1.33 0.64–2.76 0.34
2–3 228 32.9 1.08 0.52–2.26 0.69
�3 96 55.2 2.47 1.07–5.66 0.01
Year of maraviroc start �2012 681 60.9 <0.01 3.20 2.39–4.30 <0.01
<2012 127 37.3 1.00
Note: Table refers to 1,381 subjects; cases with missing values for each variable are not reported in the table; in 264 cases viral tropism was collected but no FPR was
available at the data analysis
NI: Not included in the final model
In the univariate analysis only variables with p-value <0.20 are shown. Additional variables tested but not found to be associated (p�0.20) in univariate analysis
comprised: gender, previous experience with NRTI, NNRTI, integrase inhibitors or enfuvirtide, and viral subtype.
a(� 35 vs <35 years)
All variables shown in the univariate analysis were included in the multivariable model. Variables retained in the final step of the backward elimination procedure (see
methods) are shown, all the other were excluded, except the viral tropism result than was manually included. All AOR shown are simultaneously adjusted. The FPR of
the geno2pheno[coreceptor] genotypic tropism interpretation was not included in the multivariable model due to co-linearity with tropism result.
https://doi.org/10.1371/journal.pone.0225381.t004
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Table 5. Univariate and multivariable logistic regression analysis of factors associated with virological failure at 48 weeks.
Univariate analysis Multivariable analysis
N Failure (%) p-value AOR 95% CI p-value
Age (years) <35 105 28.6 0.19 1.00 0.05
�35 897 19.1 0.58a 0.35–0.95
35–44 354 20.0
45–54 379 19.3
�55 164 16.5
Nadir CD4 count (cells/mm3) <50 195 29.7 <0.01 1.00
50–199 335 17.9 0.55 0.35–0.85 <0.01
200–349 209 16.3 0.57 0.34–0.94 0.03
�350 112 14.3 0.42 0.22–0.81 <0.01
Baseline CD4 count (cells/mm3) <50 31 32.3 <0.01 NI
50–199 170 27.6
200–349 196 20.4
�350 584 16.6
Baseline HIV-1 RNA (cps/mL) <50 473 10.1 <0.01 1.00
50–199 110 30.9 3.59 2.13–6.03 <0.01
200–4.999 182 32.4 4.45 2.83–6.98 <0.01
5.000–99.999 141 18.6 2.37 1.39–4.03 <0.01
�100.000 81 32.9 4.88 2.74–8.69 <0.01
Maraviroc daily dose <300 mg 105 21.9 0.33 NI
�300 mg 752 19.3
Maraviroc schedule Once daily 190 21.6 0.52 NI
Twice daily 498 18.5
Context of maraviroc use ART naive 32 15.6 <0.01 NI
Switch. suppressed VL 303 8.6
Switch. detectable VL 310 27.7
Intensify. suppressed VL 34 14.7
Intensify. detectable VL 37 40.5
Drug classes previously experienced <3 361 17.2 0.13
3 337 19.9
�3 311 23.5
Previous PI experience Yes 876 21.0 0.05 2.21 1.21–4.04 0.01
No 133 13.7
Previous INSTI experience Yes 456 22.4 0.07 NI
No 553 17.9
Previous enfuvirtide experience Yes 61 26.2 0.18 NI
No 948 19.5
Viral tropism R5 805 19.8 0.06 1.00
Non-R5 108 25.2 1.25 0.79–1.96 0.34
ART classes used with maraviroc (n) 1 378 15.9 0.02 NI
2 457 21.0
3 105 28.6
Concomitant PI use Yes 655 21.3 0.17
No 285 16.1
(Continued)
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multiple clinical scenarios. Its most frequent use was as a switch therapy in highly ART-experi-
enced patients with either detectable or undetectable viral load. In this population, maraviroc
use was safe and reasonably effective. Maraviroc discontinuation was mostly due to VF, desire
to simplify the treatment regimen, or issues of incomplete adherence with the regimen. Toxic-
ity accounted for 18% of the reported reasons of maraviroc discontinuation. Clearly, neither
toxicity nor VF could be specifically attributed to maraviroc, due to concomitant antiretrovi-
rals. This being a retrospective study, it was not possible to investigate the details of the toxicity
events and confirm their attribution to maraviroc or other drugs. Notably, only two cases of
transaminase elevations were reported as reasons for maraviroc discontinuation. Major
Table 5. (Continued)
Univariate analysis Multivariable analysis
N Failure (%) p-value AOR 95% CI p-value
GSS of accompanying regimen <1 73 17.8 <0.01 1.00
1 <2 191 17.3 0.82 0.64–2.76 0.61
2 <3 188 18.6 0.86 0.40–1.85 0.69
�3 65 33.8 2.14 0.90–5.09 0.08
Note: Table refers to 1009 subjects; cases with missing values for each variable are not reported in the table; in 264 cases viral tropism was collected but no FPR was
available at the data analysis. Additional variables tested but not found to be associated by univariate analysis (p>0.2): maraviroc schedule and daily dosing, gender,
ethnicity, number of previous drugs experienced, previous experience with NRTIs, or NNRTIs, viral subtype, false positive rate value of the geno2pheno[coreceptor]
genotypic tropism interpretation, and calendar year of maraviroc start.
a(� 35 vs <35 years)
All variables shown in the univariate analysis were included in the multivariable model. Variables retained in the final step of the backward elimination procedure (see
methods) are shown. all the other were excluded, except the viral tropism result that was manually included. All AOR shown are simultaneously adjusted.
https://doi.org/10.1371/journal.pone.0225381.t005
Table 6. Univariate logistic regression analysis of the association between non-standard maraviroc uses and treatment failure.
Treatment failure over 48 weeks
No Yes Total p-value� p-value��
N % N %
Dosing schedule Once daily 149 54.0 127 46.0 276 <0.01 0.01
Twice daily 406 61.4 255 38.6 661
Unknown 254 57.2 190 42.8 444
Total daily dose (mg) 150 82 49.1 85 50.9 167 <0.01 0.01
300 434 59.2 299 40.8 733
600 153 67.1 75 32.9 228
1200 20 64.5 11 35.5 31
�150 607 61.2 385 38.8 992
Unknown 120 54.1 102 45.9 222
Tropism R5 643 61.3 406 38.7 1049 <0.01 <0.01
Non-R5 107 47.8 117 52.2 224
Unknown 58 53.7 50 46.3 108
Note: all p-values were calculated by a univariate mixed logistic model that takes into account the clustering effect of the clinical centre
� p-value including unknown category
�� p-value excluding unknown category
https://doi.org/10.1371/journal.pone.0225381.t006
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determinants of treatment failure–defined as discontinuation of maraviroc for any reason or
virological failure–were the concomitant use of three or more predicted active drugs, and
more recent calendar year of maraviroc initiation (after 2011). These findings are likely to
reflect a higher propensity for maraviroc interruption in the presence of other active drugs,
and the increased number of effective drugs that have become available in recent years.
Interestingly, a significant proportion (17.6%) of patients in the cohort started maraviroc
despite carrying a non-R5 virus. Given that the classification as R5 was largely based on the
centralised re-analysis of V3 sequences, the observed off-label use of maraviroc may in part
reflect technical aspects of tropism testing and the application of different interpretation
thresholds. There also appeared to be interest in exploring maraviroc activity in patients with
mixed tropism results and in those for whom selective tissue activity was postulated (i.e.,
against virus replicating in the CNS– 5 cases indeed reported this reason for maraviroc use).
Non-R5 tropism predicted higher odds of treatment failure, however it had a weaker effect on
virological failure, with a higher proportion of patients with non-R5 virus experiencing viro-
logical failure in a univariable analysis but no clear association in the adjusted model. This sug-
gests that some of the non-standard use might have been explorative and short-term. In this
context, tropism would not be expected to be the key predictor of virological failure. In addi-
tion, in the highly treatment-experienced population we analysed, multiple determinants are
expected to impact virologic responses. There is evidence from the MOTIVATE trials of mara-
viroc in treatment-experienced patients that the composition of the overall regimen (alongside
the baseline CD4 count) is a key predictor of virologic outcome, including in a small subset of
patients with non-R5 virus [20].
About one in five patients on maraviroc had a detectable viral load after 48 weeks of follow-
up. It should be noted that the analysis of virological failure excluded patients who either previ-
ously discontinued or were lost to follow-up, and that these may have comprised cases of viro-
logical failure. Although this may be considered a high rate of virological failure (when defined
Table 7. Univariate logistic regression analysis of the association between non-standard maraviroc uses and virological failure.
Virological failure (week 48)
No Yes Total p-value� p-value��
N % N %
Dosing schedule Once daily 149 78.4 41 21.6 190 0.52 0.36
Twice daily 406 81.5 92 18.5 498
Unknown 254 78.9 68 21.1 322
Total daily dose (mg) 150 82 78.1 23 21.9 105 0.45 0.33
300 434 79.2 114 20.8 548
600 153 84.5 28 15.5 181
1200 20 87.0 3 13.0 23
�150 607 80.7 145 19.3 752
Unknown 120 78.4 33 21.6 153
Tropism R5 643 80.2 159 19.8 802 0.06 0.15
Non-R5 107 74.8 36 25.2 143
Unknown 59 90.8 6 9.2 65
Note: all p-values were calculated by a univariate mixed logistic model that takes into account the clustering effect of the clinical centre
� p-value including unknown category
�� p-value excluding unknown category
https://doi.org/10.1371/journal.pone.0225381.t007
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as a viral load>50 copies/mL), interpretation should consider the high stringency applied to
the definition of failure. Indeed, applying a higher and clinically more relevant viral load
threshold of 200 copies/mL halved the number of virological failures, indicating that a substan-
tial number of cases of viraemia were at low level. Moreover, the cohort had a significant his-
tory of treatment exposure with about two thirds of participants having previously
experienced 3 or more antiretroviral drug classes. Predictors of virological failure were a low
nadir CD4 cell count, a detectable viral load at maraviroc initiation, and a history of PI expo-
sure, with a marginal effect of younger age. In line with these findings, previous cohort studies
showed that older age reduces the risk of virological failure, likely as a result of improved medi-
cation adherence [21]. Higher baseline viral load and lower nadir CD4 counts were also associ-
ated with virological failure in other observational studies [22–24]. It should be noted that a
low nadir CD4 count may indicate the presence minority CXCR4-tropic variants which would
remain undetected by routine testing methods [25,26]. The association of higher risk of viro-
logical failure with prior PI use may reflect circumstances associated with increased PI use
including treatment failure, drug resistance and low medication adherence. Interestingly, we
found no association between the activity of the regimen accompanying maraviroc (measured
as the GSS) and virological failure. This implies that non-resistance related factors largely
accounted for virological outcomes. For example, pre-treated patients with high GSS values
may actually reflect past failures due to non-adherence to therapy. On the other hand, in a
population with extensive treatment experience, the extent of archived drug resistance and
residual drug activity despite resistance may both be underestimated [27].
The treatment collection included several cases of non-standard, off-label maraviroc use.
Indeed, it included ART-naïve subjects (unlicensed indication in Europe), patient carrying
non-R5 virus, and cases with once-daily maraviroc dosing and low daily doses of 150mg.
While we cannot exclude prescription errors, it is also realistic to assume that the drug was
deliberately used in off-label indications. Off-label use may result from lack of alternative treat-
ment options because of toxicity or drug resistance, hypothesised residual drug activity [28],
or the need for dosing simplification to once-daily regimens and lower drug dosing as sug-
gested by pharmacokinetics reports, in association with boosted PI [29]. Overall, we found evi-
dence that using maraviroc either once daily, at a low total daily dose of 150mg, or with non-
R5 virus increased the likelihood of treatment failure, but the effect on virological failure was
only marginally apparent with non-R5 virus. One relatively common use of maraviroc was
treatment intensification due to low CD4 cell counts. This reflects prior evidence of an immu-
nologic benefit of maraviroc use, independent from its antiviral efficacy, which was not con-
firmed by subsequent controlled studies [30,31].
This study has several limitations. First, no measure of medication adherence was available,
therefore this major determinant of treatment outcome could not be analysed. This is not dif-
ferent from the majority of other reported observational studies of ART outcomes, which did
not collect medication adherence systematically and could not adjust for this factor. Second,
some variables such as genotypic susceptibility of the concomitant regimen and viral subtype
were not available for a large proportion of cases, therefore their predictive value could not be
fully analysed. Third, the retrospective design of the study did not allow to confirm the reasons
for maraviroc initiation or interruption. In order to partly overcome this limitation, we used
objective data such as the pre-treatment viral load, the pre-maraviroc treatment regimen, and
the drugs prescribed concomitantly with maraviroc to classify the different clinical scenarios
of maraviroc prescription. Despite these limitations, this study is unique in depicting the clini-
cal use of maraviroc in clinical practice throughout Western Europe during the last decade.
In conclusion, in this large European survey we found that maraviroc was used in multiple
clinical scenarios involving mostly ART-experienced patients, both virologically suppressed
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and with detectable viremia. In a population of highly experienced patients, maraviroc was
overall safe and reasonably effective, also when considering that there was a considerable use
of exploratory off label treatments, and a substantial number of virological failures occurred at
viral load <200 copies/mL. High discontinuation rates in recent years presumably reflected
the availability of alternative active agents. In current guidelines, maraviroc continues to repre-
sent a valid antiretroviral option in selected patients, particularly those with limited drug
options or intolerance to agents from other classes. The virological rationale for using CCR5
antagonists early in therapy is still strong, as reflected by the significant impact of a low nadir
CD4 count on treatment outcomes [32]. Whether CCR5 antagonists exhibit additional bene-
fits beyond their antiviral activity remains to be established [33–35].
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